Replimune stock doubled to $9.00 after FDA accepted its resubmitted application for melanoma drug RP1, with decision expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback